UiPath shares gain more than 3% after quarterly results exceed estimates and AI demand grows

Traders Union
All News
Stocks
UiPath surges 3.1% today on results

Highlights

UiPath reported second quarter revenue of $410.3 million, rising 13.4% year over year and surpassing analyst expectations.
A majority of large contracts in the quarter included artificial intelligence integration and more complex enterprise-focused agreements.
Shares of UiPath gained 3.1% to $13.99, with mixed momentum and key trading range seen at $12.49 to $15.49.

Profit streak and AI deal strength drive positive enterprise sentiment

UiPath reported second quarter revenue of $410.3 million, reflecting a 13.4% year-over-year increase and exceeding analyst estimates. The company emphasized that a majority of its largest deals in the quarter featured artificial intelligence integration, pointing to more complex process orchestration and broader enterprise contracts. UiPath also achieved its fourth consecutive quarter of GAAP profitability, and a new company survey indicated that prioritizing orchestration is linked to faster scaling and higher ROI for large enterprises.

Anton Kharitonov, expert at Traders Union, views UiPath’s 13.4% revenue increase and recurring GAAP profits as positive, but sees the technical picture as weak. PATH remains stuck below key 20- and 50-day moving averages, signaling persistent selling. Kharitonov notes oversold momentum on several oscillators, plus sellers dominating short- and medium-term action. He finds that despite solid news and a session gain, the upside may be capped by strong resistance at $14.02. "Sustained reversal remains unlikely unless PATH reclaims the $14.02 level and momentum confirms a shift," he says.

Viktoras Karapetjanc, expert at Traders Union, highlights UiPath's robust quarterly revenue and continued AI integration in its largest contracts. He sees enterprise adoption and four straight profitable quarters as strong fundamental tailwinds. Karapetjanc believes the bullish structure remains intact while the price holds above the 200-day average. "With orchestration-linked growth drivers, further advances above $14.02 could unlock new opportunities for investors," he says.

Sholanke Dele, market strategist, finds sentiment muted despite upbeat revenue headlines. He points to weak trend strength and dominant selling signals on technical indicators. Dele sees risk of renewed downside unless support at $13.43 is defended. "Any pullback below $13.43 could deepen losses, so caution is warranted even with intraday strength," he says.

Mixed momentum as seller control meets long-term bullish trend

UiPath is trading below its 20-day and 50-day moving averages at $16.49 and $14.02, but above the 200-day moving average of $12.89. This setup reveals ongoing short- and medium-term resistance from sellers, while the long-term trend remains bullish relative to the 200-day average. The nearest resistance stands at $14.02, and closest support is at $13.43. Momentum readings are mixed: the MACD flashes a strong buy, but the ADX points to weak trend strength. Multiple oscillators (RSI, Stochastic RSI, and CCI) are in oversold territory, and Bull/Bear Power (BBP) at -1.82 further confirms seller dominance and an oversold bias. Recent trading saw PATH reach $13.99, gaining $0.42 after an opening gap up, with price holding near session highs and intraday volatility at 6.25%. This divergence highlights strengthening intraday interest against a broader backdrop of mixed momentum and downside risk.

Earlier, analysts noted that UiPath faced persistent downside risks and continued technical weakness, with momentum skewed to the downside. The latest data add a positive dimension through revenue growth and AI-driven contract wins, but the prevailing scenario remains one of near-term consolidation, with traders advised to monitor the $14.02 resistance for signs of a possible breakout toward the top of the projected range.

Source of Data: PATH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.